5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chroman-3-one | 133196-83-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chroman-3-one
• 英文别名: 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-3-one
• CAS: 133196-83-5
• 化学式: C₁₅H₁₂O₅
• 分子量: 272.257
• InChiKey: DHOUAADDXACZIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
  申请人：United Therapeutics Corporation

  公开号：US20150259274A1

  公开（公告）日：2015-09-17

  This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

  这项发明通常涉及前列环素配方及其在促进血管舒张、抑制血小板聚集和血栓形成、刺激溶栓、抑制细胞增殖（包括血管重塑）、提供细胞保护、预防动脉粥样硬化和诱导血管生成方面的用途方法。
• ANTIBACTERIAL AGENT
  申请人：JUNTENDO EDUCATIONAL FOUNDATION

  公开号：US20150322033A1

  公开（公告）日：2015-11-12

  An antibacterial agent comprising a compound represented by the following general formula (I), which can exhibit potent antibacterial activity against bacteria that have acquired resistance to quinolones (in the formula, R 1 and R 4 represents hydrogen atom, hydroxyl group, or a lower alkoxy group; R 2 and R 3 represents hydrogen atom or hydroxyl group; W represents hydrogen atom, a lower cyclic alkyl group, or a lower alkoxy group; R 1′ and R 5′ represents hydrogen atom; R 2′ and R 3′ represents hydrogen atom, hydroxyl group, or a lower alkoxy group; and R 4′ represents hydrogen atom or hydroxyl group).

  一种抗菌剂，包括以下一般式（I）所代表的化合物，该化合物可以对已经对喹诺酮产生抗药性的细菌表现出强效的抗菌活性（在该式中，R1和R4代表氢原子、羟基或较低的烷氧基；R2和R3代表氢原子或羟基；W代表氢原子、较低的环烷基或较低的烷氧基；R1'和R5'代表氢原子；R2'和R3'代表氢原子、羟基或较低的烷氧基；R4'代表氢原子或羟基）。
• LIQUIRITIGENIN AND DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS
  申请人：COHEN Isaac

  公开号：US20080319051A1

  公开（公告）日：2008-12-25

  The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.

  本公开提供了含甘草素、衍生物或前药的组合物，作为雌激素受体β选择性激动剂，可用于治疗更年期症状和雌激素依赖性疾病。同时，本公开还提供了使用该组合物治疗上述症状和疾病的方法。
• [EN] COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：NUSIRT SCIENCES INC

  公开号：WO2018058109A1

  公开（公告）日：2018-03-29

  Methods and compounds useful for reducing, treating, preventing, or sustaining the reduction of a metabolic disease or disorder are provided herein. Also provided herein are compositions and kits for practicing any of the methods described herein.

  本文提供了用于减少、治疗、预防或维持代谢性疾病或紊乱的方法和化合物。本文还提供了用于实施本文中描述的任何方法的组合物和工具包。
• Compounds and methods for delivery of prostacyclin analogs
  申请人：Phares Ken

  公开号：US20050085540A1

  公开（公告）日：2005-04-21

  This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

  本发明涉及前列环素类似物及其在促进血管扩张、抑制血小板聚集和血栓形成、刺激溶栓、抑制细胞增殖（包括血管重塑）、提供细胞保护、预防动脉粥样硬化和诱导血管生成方面的应用方法。一般而言，本发明的化合物和方法在口服给药时增加了曲前列素的口服生物利用度和循环浓度。本发明的化合物具有以下公式：